Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

We recently compiled a list of the 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where GSK ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Ukrainian President Volodymyr Zelensky appeared on Fox News shortly after his Oval Office meeting with President Donald Trump and Vice President JD Vance broke down into an angry exchange. Supreme ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February ...

About the Zymeworks and GSK Collaboration In April 2016 ... includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section ...